Skip to content

Study · Not a test of the peptide alone · 2017

1 result

Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.

Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M

The Tokai journal of experimental and clinical medicine20 Sept 2017Cited by 21 (Europe PMC)

PMID28871578 (opens in a new tab)PepBankPUB-28871578
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneCase report or seriesActivity measurement

    In a patient with secondary adrenal insufficiency after nivolumab, the TRH, LH-RH and GHRP‑2 tests together showed that only ACTH function was destroyed.

    In plain wordsIn one patient, a set of hormone tests that included GHRP‑2 showed that only the ACTH hormone was lost.

    Peptide
    GHRP-2
    Outcome
    Not applicableAnterior pituitary function in GHRP-2 test with other stimulation tests
    Study

    n = 1

    Outcome group
    Stress hormones · Endocrine and hormones

    Source sentences

    Summary
    Moreover, the results of the thyrotropin-releasing hormone (TRH), luteinizing hormone-releasing hormone (LH-RH) and growth hormone-releasing peptide-2 (GHRP-2) tests showed that only the ACTH function was destroyed (isolated ACTH deficiency).
    1 context sentence
    Summary · context
    Here, we report a patient with metastatic renal cell carcinoma who presented with secondary adrenal insufficiency following nivolumab therapy.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.